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ﬁed in groups at ﬁve different levels: ﬁrst level, the organ or system
on which they act; second and third levels indicate therapeutic/phar-
macological subgroups; the fourth level is a therapeutic/pharmacologi-
cal/chemical subgroup and the ﬁfth level is the chemical substance.
The analyses consisted in two stages. In theﬁrst stage, they performed
a conventional matched case–control approach using conditional logisticThe study performed by Pottegård and colleagues, published in this sociated with a particular cancer or with cancer overall, and ii) dose–issue of EBioMedicine (Pottegård et al., 2016), falls within the clinically
relevant scientiﬁc ﬁeld which focuses on the variability in human drug
response (Bruno et al., 2014; Fitzgerald, 2005). In some predisposed in-
dividuals, treated with a therapeutic dose of a drug, exaggerated re-
sponses (serious adverse events) can occur. These responses become
evident when drugs, usually marketed at a limited number of doses,
are broadly used in the population. Similarly, in some individuals drug
therapies can result more effective than in the rest of exposed patients.
The sources of heterogeneity among individuals in drug responses in-
volve individual variability in genes, environment and lifestyle for
each person. The occurrence of these determinants in drug response
has provided the basis for the development of precision medicine,
i.e., prevention and treatment strategies that take individual variability
into account (FitzGerald, 2015; Collins and Varmus, 2015). While
some advances in precision medicine have been made, the practice is
not currently in use for most diseases.
Health-care information technology is advancing rapidly, creating
new opportunities for the accurate reconstruction of comprehensive
drug-exposure histories of individuals. Here, Pottegård et al. (2016)
have used this approach to address their hypothesis that pharmaceuti-
cal agents may possess long-term carcinogenic or chemopreventive
properties that are not identiﬁed by the premarketing genotoxicity
and carcinogenicity testing or the preclinical trials. Thus, they per-
formed a large-scale systematic screening for identifying associations
between prescribed drugs and cancer risk using the high quality Danish
nationwide health and demographic registries. Drugs were categorized
according to the Anatomical Therapeutic Chemical (ATC) index, a hier-m.2016.03.018.
e, Imaging and Clinical Sciences
icine, Chieti, Italy.
. This is an open access article underregression. In the second stage, those associationswere examined accord-
ing to two additional criteria: i) speciﬁcity, i.e., whether the drug was as-
response relationship.
In this study, 22,125 drug-cancer pairs were evaluated. Among them,
1020 signals (i.e., drug-cancer associations) met the criteria for strength
of association, speciﬁcity and dose–response pattern. The majority of
the identiﬁed signals indicated an increase cancer risk and a smaller pro-
portion of signals revealed a potential chemopreventive effect. The analy-
sis of cancer risk association with the use of single drugs (ﬁfth ATC level)
(510 signals) suggested that 33% and 67% of themwere linked to a reduc-
tion and an increase of cancer risk, respectively.
The screening algorithmwas successful in identifyingwell-established
causal associations, e.g., between female hormone and risk of breast can-
cer (International Agency for Research on Cancer, 2007).Moreover, it was
conﬁrmed an association between the photosensitizing antihypertensive
drug hydrochlorothiazide and lip cancer (Friedman et al., 2012).
The use of the antiplatelet agent aspirin [acetylsalicylic acid, an in-
hibitor of thromboxane A2-dependent platelet activation (Patrignani
and Patrono, 2015)] was inversely correlated with hepatocellular carci-
noma (HCC) and larynx cancer. Interestingly, the use of the antiplatelet
agent dipyridamole, an inhibitor of cAMP-phosphodiesterase which
also exhibits anti-inﬂammatory and anti-oxidant properties (Weyrich
et al., 2005), was inversely correlated with HCC. The protective effect
of antiplatelet agents (such as aspirin and clopidogrel) has been demon-
strated in a mouse model of hepatitis B virus-associated liver cancer
(Sitia et al., 2012). Antiplatelet agents may act as anti-cancer drugs by
inhibiting the release of several platelet mediators which may contrib-
ute to the development of chronic inﬂammation associated with HCC.
Several lines of evidence support the chemopreventive effect of the
antiplatelet drug low-dose aspirin against colorectal cancer
(Patrignani and Patrono, 2015) thus leading the United States
Preventive Services Task Force to recommend its use for the primary
prevention of cardiovascular disease and colorectal cancer (http://
www.uspreventiveservicestaskforce.org/Page/Document/draft-the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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and-cancer). However, this protective signal was not detected in the
present study.
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) have been
shown to have a chemopreventive effect in patients with sporadic
colorectal adenomas via the inhibitory effect on the biosynthesis of
the protumorigenic prostaglandin E2 (Patrignani and Patrono,
2015).This is conﬁrmed in the present study showing that some indi-
vidual drugs of the class, i.e., tolfenamic acid and diclofenac, were
negatively associated with colon and rectum adenocarcinomas,
respectively.
The study by Pottegård et al. (2016) has several points of strength in-
cluding thedetailed stratiﬁcation according to cancer histology and clin-
ical data collection in large-scale population which allowed evaluation
of drug exposure for more rare cancers. However, it is characterized
by importantweakness related to the fact that this study lacks of adjust-
ment for potential confounding from lifestyle, such as obesity, alcohol
consumption, and smoking.
The approach of addressing hypotheses by the analysis of large-scale
electronic medical records may capture unexpected responses to drugs
in the population; however, the time is ripe to pursue new strategies
that will take into account individual variability in genes, environment,
and lifestyle for each person (Fitzgerald, 2005, 2015). The new approach
integrates electronic medical records with biobank data to identify new
disease pathways.Moreover, deep phenotyping of small numbers of pa-
tients will allow to elucidate the functional signiﬁcance of genomic var-
iation (Fitzgerald, 2005, 2015). This change in drug development will
permit the use of safer and more efﬁcacious medicines.
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